Toxic epidermal necrolysis (TEN) is a rare and serious skin condition. Often, it’s caused by an adverse reaction to medication like anticonvulsants or antibiotics.The main symptom is severe skin peeling and blistering. The peeling progresses quickly, resulting in large raw areas that may ooze or weep. It also affects the mucous membranes, including the mouth, throat, eyes, and genital region.

The global Toxic Epidermal Necrolysis (TEN) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Toxic Epidermal Necrolysis (TEN) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Toxic Epidermal Necrolysis (TEN) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Toxic Epidermal Necrolysis (TEN) in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Toxic Epidermal Necrolysis (TEN) include Mölnlycke Health Care, maxill inc, Cadila Pharmaceuticals, BD, Schulke India Pvt. Ltd, Smith & Nephew, Basic Pharma Life Science P Ltd., PSK Pharma and Avrio Health L.P., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Toxic Epidermal Necrolysis (TEN), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Toxic Epidermal Necrolysis (TEN).

The Toxic Epidermal Necrolysis (TEN) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Toxic Epidermal Necrolysis (TEN) market comprehensively. Regional market sizes, concerning products by disease type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Toxic Epidermal Necrolysis (TEN) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by disease type, by application, and by regions.


By Company


Mölnlycke Health Care

maxill inc

Cadila Pharmaceuticals

BD

Schulke India Pvt. Ltd

Smith & Nephew

Basic Pharma Life Science P Ltd.

PSK Pharma

Avrio Health L.P.

3M

Biesterfeld AG

Vesismin Health

Mylan N.V.

Segment by Disease Type

Neonatal Patients

Adolescent Patients

Adult Patients


Segment by Application


Hospital

Diagnostic Center

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by disease type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Toxic Epidermal Necrolysis (TEN) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by disease type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.